help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Luisi, S.
Right arrow Articles by Genazzani, A. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Luisi, S.
Right arrow Articles by Genazzani, A. R.
The Journal of Clinical Endocrinology & Metabolism Vol. 85, No. 7 2429-2433
Copyright © 2000 by The Endocrine Society


Original Studies

Serum Allopregnanolone Levels in Pregnant Women: Changes during Pregnancy, at Delivery, and in Hypertensive Patients

S. Luisi, F. Petraglia, C. Benedetto, R. E. Nappi, F. Bernardi, M. Fadalti, F. M. Reis, M. Luisi and A. R. Genazzani

Department of Reproductive Medicine and Child Development, Section of Gynecology and Obstetrics (S.L., F.B., A.R.G.), University of Pisa, Pisa; Department of Surgical Sciences, Chair of Obstetrics and Gynecology (F.P., M.F., F.M.R.), University of Udine, 33100 Udine; Department of Obstetrics and Gynecology (C.B.), University of Turin, Turin; Department of Obstetrics and Gynecology (R.E.N.), University of Pavia, Pavia; and Endocrine Research Unit, Consiglio Nazionale delle Ricerche (M.L.), Pisa, Italy

Address correspondence and requests for reprints to: Felice Petraglia, M.D., Department of Surgical Sciences, Chair of Obstetrics and Gynecology, University of Udine, piazzale S. Maria della Misericordia, 33100 Udine, Italy. E-mail: felice.petraglia{at}dsc.uniud.it


    Abstract
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Allopregnanolone is a neuroactive steroid measurable in peripheral circulation. The aim of the present study was to investigate the presence and the possible changes in serum allopregnanolone and progesterone levels in pregnant women during gestation, at delivery, and in patients with chronic hypertension, with or without superimposed preeclampsia. We also evaluated allopregnanolone in cord blood. Three groups of pregnant women were studied: 1) healthy controls followed longitudinally throughout gestation (n = 14); 2) at vaginal or cesarean delivery (n = 66); and 3) with chronic hypertension (n = 12), with (n = 7) or without (n = 5) superimposed preeclampsia. Allopregnanolone and progesterone levels were measured in maternal and cord serum by RIA. In healthy pregnant women, serum allopregnanolone and progesterone levels progressively increased throughout gestation. Whereas no changes were found at vaginal delivery, serum allopregnanolone and progesterone levels were significantly lower at delivery by emergency cesarean section (P < 0.01). Umbilical cord serum allopregnanolone and progesterone levels in emergency cesarean were significantly lower than those found at vaginal delivery (P < 0.01). Patients with chronic hypertension, with or without superimposed severe preeclampsia, showed serum allopregnanolone levels significantly higher than those of healthy women at the same gestational age (P < 0.01). In conclusion, maternal serum allopregnanolone levels increased during normal gestation were lower in women who underwent emergency cesarean and higher in patients with chronic hypertension, with or without preeclampsia. Because allopregnanolone is active on the central nervous system and in the control of systemic blood pressure, an involvement of this neurosteroid in the adaptive processes induced by pregnancy is suggested.


    Introduction
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
THE ROLE OF progesterone and its metabolites in human pregnancy and at parturition has been discussed for a long time. Presently, the gestational-related increase of maternal progesterone serum levels and the lack of marked changes during labor are part of a well established picture (1, 2, 3). However, the evidence that during spontaneous labor progesterone levels are higher than at elective cesarean section (4) and that myometrial progesterone receptor concentrations is higher during active labor than before labor (5) again supported a role of progesterone in human parturition. In addition, there was a reduced uterine 5{alpha}-reductase activity before spontaneous labor (6), whereas a decrease of maternal serum 5{alpha}-dihydroprogesterone level during the last 10 days preceding spontaneous delivery (2) has been also shown.

The inhibiting action of progesterone on the uterine contractile activity during pregnancy could be mediated via the metabolite 3{alpha}-hydroxy-5{alpha}pregnan-20-one (allopregnanolone), which augments the myorelaxant function of GABA-A uterine receptors (7, 8, 9). This hormone is measurable in systemic circulation of pregnant and nonpregnant women, and because it is also neuroactive, allopregnanolone may contribute to the psychological adaptation associated with pregnancy and puerperium (10). In addition, because progesterone influences the vascular adaptation throughout gestation, a possible role of progesterone in hypertensive disturbances of pregnant women has been hypothesized (11, 12, 13). However, the measurement of maternal serum progesterone levels did not result in a powerful index of placental function, and neither serum progesterone nor 5{alpha}-dihydroprogesterone levels identified women at risk of developing pregnancy-induced hypertension or other maternal pathological conditions (14, 15).

Following the development of a new assay to measure serum allopregnanolone levels, it has been shown that changes in healthy women are not fully dependent on progesterone changes (16); therefore, the present study aimed to evaluate: 1) the changes of maternal serum allopregnanolone levels and its relationship with progesterone throughout gestation in healthy women; 2) whether serum and umbilical cord serum allopregnanolone and progesterone levels vary according to the different modes of parturition; and 3) the changes of maternal serum allopregnanolone and progesterone levels in women with chronic hypertension, with or without superimposed preeclampsia.


    Materials and Methods
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Subjects

The present study included nulliparous pregnant women (n = 66; 23–35 yr of age), who were subdivided in the following groups:

Group 1.This group comprised healthy pregnant women (n = 14) longitudinally studied throughout gestation (blood sample collected every 5 weeks, starting from 5–6 weeks until 39–40 weeks).

Group 2.The different modes of parturition (between 38 and 41 weeks of gestation) were studied in pregnant women who had a physiological spontaneous labor (n = 40), in women who underwent elective (breech presentation) cesarean section (n = 13) or emergency (fetal distress) cesarean section (n = 13).

Group 3.In this group, women with chronic hypertension (n = 12) matched to controls for maternal age were longitudinally studied throughout gestation. They were distinguished into two study populations: 1) women (n = 5) who remained with chronic hypertension, without superimposed preeclampsia; and 2) patients (n = 7) who developed severe preeclampsia [according to the WHO criteria, Study Group for the Hypertensive Disorders of Pregnancy: persistent elevation of blood pressure >=160 mm Hg (systolic) or >=110 mm Hg (diastolic) and proteinuria >300 mg/dL, after the 20th week of gestation) (17). All women were screened for gestational diabetes with Carpenter’s test. None of the women included in the study developed gestational diabetes. The study was approved by a local institutional Ethical Committee, and all participants provided informed consent.

Blood sampling

Maternal cubital venous blood was collected throughout gestation (groups 1 and 3), during spontaneous labor (cervical dilatation, >=2 cm), and at vaginal delivery (group 2) and before and at the time of cesarean delivery (group 2). Mixed umbilical cord blood was collected immediately after birth in group 2.

In each subject a blood sample was drawn between 0700 and 0900 h. Blood samples were centrifuged, and serum was stored at -20 C until assayed.

Allopregnanolone and progesterone assays

Analytic grade solvents were purchased from Merck & Co., Inc.(Darmstadt, Germany); C-18 Sep-Pak cartridge was obtained from Waters Corp. (Milford, MA). Standard allopregnanolone was purchased from Sigma (St. Louis, MO), and pregna-3{alpha}-ol-20-one, 5{alpha}-[9,11,12,–3H(N)] (45 Ci/nmol) was obtained from Amersham Pharmacia Biotech (Little Chalfont, UK). The polyclonal antisera raised in sheep against allopregnanolone carboxymethyl ether coupled with BSA was kindly provided by Dr. R. H. Purdy (Department of Psych., Veterans Administration Hospital, San Diego, CA). Serum samples (1 mL) were thawed. Standard solutions of allopregnanolone (0, 15.6, 31.2, 62.5, 125.0, 250.0, 500, and 1000 pg steroid per tube) were prepared in steroid-free serum (pooled human serum stripped from endogenous steroids by repeated treatment with charcoal: 50 mg/mL), recovery standard of tritium-labeled steroid was added (1200–1500 cpm), and the samples were extracted twice with 8 mL diethyl ether. The organic phase was removed and evaporated to dryness in Universal Vacuum System Plus (Savant, Rome, Italy).

The extracts were eluted with assay buffer (20 mM sodium phosphate in saline containing sodium azide and BSA, 0.1 g/L each) and divided into two aliquots each of 500 µL corresponding to 500 µL serum. The samples in duplicate were passed through a C18 Sep-Pak cartridge, previously equilibrated with a solution of aqueous methanol (50:50 v/v) containing 1% acetic acid and 50% aqueous methanol, and the elution of allopregnanolone was performed with absolute methanol (10 mL) (16). The dry extracts were then assayed by RIA: the radioligand (7000 cpm) and the antibody (working dilution, 1:4000, vol/vol), 100 µl each, dissolved in the assay buffer were added to the tubes containing samples and standards, and the volume was adjusted to 500 µL with buffer. The samples for determination of nonspecific binding contained only the radioligand. After vortex-mixing and overnight incubation at 4 C, bound and free steroids were separated by dextran-charcoal adsorption (0.25 g charcoal, 0.025 dextran 70 in 100 mL of assay buffer, 0.5 mL), followed by centrifugation at 4 C for 10 min. Radioactivity of supernatants was measured in a liquid scintillator spectrometer equipped with a program for cpm counting and RIA calculation (16). After extraction with ether, the recovery of labeled allopregnanolone was 96.3 ± 4.8%, after extraction and chromatography it was 87.5 ± 7.9%, and for the entire procedure the recovery of unlabeled standard allopregnanolone was 77.5 ± 9.8%. The sensitivity of the assay, expressed as a minimal amount of allopregnanolone distinguishable from the zero sample with 95% probability, was 15–20 pg/tube, and the intra- and interassay coefficients of variation were 7.2% and 9.1%, respectively. A parallelism test was also performed: a sample containing a high concentration of standard unlabeled allopregnanolone (~2000 pg/mL) has been diluted with zero standard, showing the results reported in a previous publication (16).

Serum progesterone was determined, after ether extraction and chromatographic partition on C18 Sep-Pak cartridge, by RIA using a commercially available kit (Radim SpA, Pomezia, Italy); the sensitivity of the assay was 50 pg/tube, and the intra- and interassay coefficients of variation were 6.5% and 8.7%, respectively.

Statistical analysis

Data are shown as means ± SEM. Data were analyzed either by one-way ANOVA (mode of delivery) or by ANOVA with repeated measures (longitudinal study), followed by Duncan’s post hoc multiple comparisons. Linear correlation coefficients were calculated to assess a possible correlation between serum allopregnanolone, serum progesterone, and blood pressure. Significance was set at P < 0.05.


    Results
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Healthy pregnancy

In healthy pregnant women, serum allopregnanolone and progesterone levels showed a significant increase during pregnancy, with highest levels at term (P < 0.01, repeated measures ANOVA, Fig. 1Go). Starting from 20 weeks of gestational age, serum progesterone levels were significantly higher than allopregnanolone levels (P < 0.01, Fig. 1Go). No significant correlation between allopregnanolone and progesterone levels was found in healthy pregnant women at any gestational age.



View larger version (15K):
[in this window]
[in a new window]
 
Figure 1. Serum allopregnanolone and progesterone levels correlate with weeks of gestation in healthy pregnant women.

 
Hypertension in pregnancy

Patients with chronic hypertension, with or without severe preeclampsia, both during the 2nd and 3rd trimester of gestation, showed mean serum allopregnanolone levels significantly higher than healthy pregnant women (Fig. 2Go). In detail, the group with chronic hypertension without preeclampsia had higher allopregnanolone levels with respect to control subjects from 20 weeks of gestation (36.9 ± 0.6 vs. 30.1 ± 1.2 ng/mL, P < 0.05) until 40 weeks (57.0 ± 1.0 vs. 50.8 ± 1.1 ng/mL, P < 0.05). The group of hypertensive women who later developed preeclampsia had still higher levels of allopregnanolone compared with the remaining groups throughout gestation (P < 0.01, Fig. 2Go). Maternal serum progesterone levels displayed a high variability between hypertensive subjects, without reaching any statistical difference in comparison with healthy pregnant women (Fig. 2Go). Serum allopregnanolone levels did not correlate with progesterone levels or with blood pressure at any gestational age in pregnant women with hypertension.



View larger version (17K):
[in this window]
[in a new window]
 
Figure 2. Serum allopregnanolone (A) and progesterone (B) levels correlate with weeks of gestation in healthy pregnant women and in pregnant women with chronic hypertension (CH) without preeclampsia and in patients with CH and superimposed preeclampsia (CH+PE). *P < 0.05 vs. healthy controls (Duncan’s test).

 
Labor and delivery

Maternal serum allopregnanolone and progesterone levels observed during normal spontaneous labor and at delivery were not result significantly different from values present at term (Fig. 3Go). Progesterone levels were significantly higher in umbilical cord than in maternal serum (P < 0.01 vs. early labor and delivery), whereas allopregnanolone levels in the two compartments were not significantly different (Fig. 3Go). No significant correlation between allopregnanolone and progesterone levels was found in the maternal circulation or in umbilical cord serum.



View larger version (24K):
[in this window]
[in a new window]
 
Figure 3. Mean ± SEM serum allopregnanolone (A) and progesterone (B) levels change according to the different modes of parturition in early labor (2 cm of dilatation), delivery, and umbilical cord serum. Women who delivered vaginally after spontaneous labor ({square}) are compared with those who delivered by elective () or emergency ({blacksquare}) cesarean section. a, P < 0.01 vs. early labor and delivery. b, P < 0.01 vs. spontaneous labor. c, P < 0.01 vs. spontaneous labor and P < 0.05 vs. elective cesarean section. d, P < 0.01 vs. early labor. e, P < 0.001 vs. spontaneous labor and P < 0.01 vs. elective cesarean section.

 
At elective cesarean delivery, maternal serum allopregnanolone and progesterone levels were in the same range of values found at term and at vaginal delivery. On the other hand, umbilical cord serum allopregnanolone and progesterone levels were significantly lower after elective cesarean section than at vaginal delivery following spontaneous labor (P < 0.01 vs. spontaneous labor, Fig. 3Go). At emergency cesarean section, immediately before surgery, maternal allopregnanolone concentrations were significantly higher than at vaginal delivery (P < 0.01 vs. spontaneous labor, P < 0.05 vs. elective cesarean section), and a significant decrease was found at delivery (P < 0.01 vs. early labor, Fig. 3Go). Umbilical cord serum allopregnanolone and progesterone levels after emergency cesarean section were both significantly lower than at vaginal delivery (P < 0.001 vs. spontaneous labor, P < 0.01 vs. elective cesarean section). No correlation was found between allopregnanolone and progesterone in maternal circulation or umbilical cord serum during elective or emergency cesarean section.


    Discussion
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
The present study showed that in healthy pregnant women maternal serum allopregnanolone and progesterone levels significantly increased throughout gestation. No major changes were found at delivery, with the exception of a significant decrease of maternal and cord serum allopregnanolone levels during emergency cesarean section. Furthermore, in patients with chronic hypertension, with or without preeclampsia, serum allopregnanolone levels were significantly higher than in healthy pregnancy. The changes of these two hormones in maternal and umbilical cord serum are correlated with gestation, but not with parturition, either in healthy women or in hypertensive patients.

The present study indicates for the first time that allopregnanolone is a circulating steroid hormone whose serum levels increase during pregnancy, in parallel with serum progesterone levels, suggesting a common origin. Even though other different sources may contribute to the two hormones, ovary and/or placenta are the most putative sources. A previous study suggested that an increased production rate of progesterone during pregnancy provides the intrauterine tissues with more substrate for the formation of 5{alpha}-dihydroprogesterone and allopregnanolone (18). However, some discrepancy is observed at delivery and in hypertensive patients, indicating that some physiological or pathological events reveal another source(s) for allopregnanolone. The lack of correlation between maternal and cord serum progesterone and allopregnanolone levels at the time of delivery, independently from the mode of parturition, supports a different source(s) for allopregnanolone in both compartments. Indeed, a maternal adrenal cortex or pituitary origin has been recently shown in healthy nonpregnant women (16).

At emergency cesarean section both maternal and umbilical serum allopregnanolone and progesterone concentrations behaved differently from the other modes of parturition, and these changes may be explained by fetal distress. The significant decrease of maternal serum and umbilical cord serum allopregnanolone levels observed during emergency cesarean section cannot be exclusively explained by the surgery because it was absent at elective cesarean section. The present finding did not confirm the previous observation of higher maternal plasma progesterone levels at vaginal delivery than at elective cesarean section (4), and this was probably due to the different experimental design of the two studies.

Still uncertain is the role of allopregnanolone in pregnancy. A potential effect of allopregnanolone in uterine kinetics has been suggested (7, 8, 9), even though an in vitro study showed that progesterone metabolites are not crucial for uterine contractions (6). A current hypothesis is the possible correlation between maternal anxiety state and serum allopregnanolone levels, given the potent anxiolytic effect of this neuroactive steroid (19, 20).

The evidence of increased levels of serum allopregnanolone in hypertensive pregnant women is of great interest in view of the possible role of progesterone in vascular tension during pregnancy. Recent evidence suggests that the control of systemic blood pressure during pregnancy may be modulated by steroid hormones (4, 6, 21, 22). Indeed, progesterone modulates the antihypertensive effect of calcitonine gene-related peptide postpartum in the rat (21). Allopregnanolone may contribute to the adaptation of baroflex control of sympathetic outflow and heart rate in pregnant rats (22). Likely, in pregnant women with chronic hypertension, the elevation of allopregnanolone levels may be compensatory to this condition and represent an attempt on behalf of the maternal or fetal organism to lower maternal blood pressure levels. Moreover, direct vascular effects of estradiol and progesterone on isolated omental artery from normotensive and preeclamptic pregnant women supported the idea of a direct in vitro vasodilator activity of progesterone, partially dependent on the endothelium (23). However, plasma progesterone and its metabolite levels did not show any significant difference in women at risk of developing pregnancy-induced hypertension (1, 14). On the other hand, a significant high amniotic fluid progesterone concentration has been reported in pregnant women who later developed preeclampsia (24).

In conclusion, our present results demonstrated a significant increase of maternal serum allopregnanolone levels during pregnancy, with high levels in chronic hypertension and low maternal and umbilical allopregnanolone and progesterone levels in women at emergency cesarean section. The lack of correlation between progesterone and allopregnanolone over parturition and in hypertensive patients may be due to an extraplacental source and/or to a different role of allopregnanolone in the behavioral and cardiovascular adaptive response during pregnancy and delivery.

Received July 7, 1999.

Revised December 29, 1999.

Accepted January 30, 2000.


    References
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Fuchs AR, Fuchs P. 1984 Endocrinology of human parturition: a review. Br J Obstet Gynecol. 91:948–967.[Medline]
  2. Lofgren M, Backstrom T, Joelsson I. 1988 Decrease in serum concentration of 5 {alpha}-pregnane-3,20-dione prior to spontaneous labor. Acta Obstet Gynecol Scand. 67:467–470.[Medline]
  3. Mathur RS, Landgrebe S, Williamson HO. 1980 Progesterone, 17-hydroxyprogesterone, estradiol, and estriol in late pregnancy and labor. Am J Obstet Gynecol. 136:25–27.[Medline]
  4. Lofgren M, Backstrom T. 1997 High progesterone is related to effective human labor. Study of serum progesterone and 5{alpha}-pregnane-3:20-dione in normal and abnormal deliveries. Acta Obstet Gynecol Scand. 76:423–430.
  5. Rezapour M, Backstrom T, Lindblom B, Ulmsten U. 1997 Sex steroid receptors and human parturition. Obstet Gynecol. 89:918–924.[CrossRef][Medline]
  6. Lofgren M, Holst J, Backstrom T. 1992 Effects in vitro of progesterone and two 5a-reduced metabolites, 5{alpha}-pregnane-3,20-dione and 5{alpha}-pregnane-3{alpha}-ol-20-one on contracting human myometrium at term. Acta Obstet Gynecol Scand. 71:28–33.[Medline]
  7. Putnam CD, Brann DW, Kolbeck RC, Mahesh VB. 1991 Inhibition of uterine contractility by progesterone and progesterone metabolites: mediation by progesterone and {gamma} amino butyric acidA receptor systems. Biol Reprod. 45:266–272.[Abstract]
  8. Majewska MD, Falkay G, Baulieu EE. 1989 Modulation of uterine GABAA receptors during gestation and by tetrahydroprogesterone. Eur J Pharmacol. 174:43–47.[CrossRef][Medline]
  9. Majewska MD, Vaupel DB. 1991 Steroid control of uterine motility via {gamma}-aminobutyric acidA receptors in the rabbit: a novel mechanism? J Endocrinol. 13:427–434.
  10. Majewska MD, Ford-Rice R, Falkay G. 1989 Pregnancy-induced alterations of GABAA receptor sensitivity in maternal brain: an antecedent of postpartum "blues"? Brain Res. 482:397–401.[CrossRef][Medline]
  11. Radwanska E. 1993 The role of reproductive hormones in vascular disease and hypertension. Steroids. 58:605–610.[CrossRef][Medline]
  12. Liao QP, Buhimaschi IA, Saade G, Chwalisz K, Garfield RE. 1996 Regulation of vascular adaptation during pregnancy and post-partum: effects of nitric oxide inhibition and steroid hormones. Hum Reprod. 11:2777–2784.[Abstract/Free Full Text]
  13. Buhimaschi I, Yallampalli C, Chwalisz K, Garfield RE. 1995 Pre-eclampsia-like conditions produced by nitric oxide inhibition: effects of L-arginine, D-arginine and steroid hormones. Hum Reprod. 10:2723–2730.[Abstract/Free Full Text]
  14. Dawood MY. 1976 Circulating maternal serum progesterone in high-risk pregnancies. Am J Obstet Gynecol. 125:832–840.[Medline]
  15. Parker Jr CR, Everett RB, Quirk Jr JG, Whalley PJ, Gant NF. 1979 Hormone production during pregnancy in the primigravid patient. I. Plasma levels of progesterone and 5-{alpha}-pregnane-3,20-dione throughout pregnancy of normal women and women who developed pregnancy-induced hypertension. Am J Obstet Gynecol. 135:778–782.[Medline]
  16. Genazzani AR, Petraglia F, Bernardi F, et al. 1998 Circulating levels of allopregnanolone in humans: gender, age, and endocrine influences. J Clin Endocrinol Metab. 83:2099–2103.[Abstract/Free Full Text]
  17. Davey DA, MacGillivray I. 1986 The classification, and definition of the hypertensive disorders of pregnancy. Clin Exp Hypertens B. 5:97–133.
  18. Dombroski RA, Casey ML, MacDonald PC. 1997 5-{alpha}-dihydroprogesterone formation in human placenta from 5{alpha}-pregnan-3ß/{alpha}-ol-20-ones and 5-pregnan-3ß-yl-20-one sulfate. J Steroid Biochem Mol Biol. 63:155–163.[CrossRef][Medline]
  19. Goascogne C, Jo DH, Corpechot C, Simon P, Baulieu EE, Robel P. 1991 Neurosteroids: byosynthesis, metabolism and function of pregnenolone and dehydroepiandrosterone in the brain. J Steroid Biochem Mol Biol. 40:71–81.[CrossRef][Medline]
  20. Bitran D, Shiekh M, MacLeod M. 1995 Anxiolytic effect of progesterone is mediated by the neurosteroid allopregnanoloneregnanolone at brain GABAa receptors. J Neuroendocrinol. 7:171–177.[CrossRef][Medline]
  21. Gangula PR, Wimalawansa SJ, Yallampalli C. 1997 Progesterone up-regulates vasodilator effects of calcitonin gene-related peptide in N(G)-nitro-L-arginine methyl ester-induced hypertension. Am J Obstet Gynecol. 176:894–900.[CrossRef][Medline]
  22. Masilamani S, Heesch CM. 1997 Effects of pregnancy and progesterone metabolites on arterial baroreflex in conscious rats. Am J Physiol. 272:R924–R34.
  23. Belfort MA, Saade GR, Suresh M, Vedernikov YP. 1996 Effects of estradiol-17 ß and progesterone on isolated human omental artery from premenopausal nonpregnant women and from normotensive and preeclamptic pregnant women. Am J Obstet Gynecol. 174:246–253.[CrossRef][Medline]
  24. Jarczok T, Zwirner M, Schindler AE. 1987 Progesterone and 5 {alpha}-pregnane-3,20-dione in human amniotic fluid. Exp Clin Endocrinol. 89:39–47.[Medline]



This article has been cited by other articles:


Home page
J. Neurosci.Home page
G. van Wingen, F. van Broekhoven, R. J. Verkes, K. M. Petersson, T. Backstrom, J. Buitelaar, and G. Fernandez
How Progesterone Impairs Memory for Biologically Salient Stimuli in Healthy Young Women
J. Neurosci., October 17, 2007; 27(42): 11416 - 11423.
[Abstract] [Full Text] [PDF]


Home page
J EndocrinolHome page
R. Kancheva, M. Hill, D. Cibula, H. Vcelakova, L. Kancheva, J. Vrbikova, T. Fait, A. Parizek, and L. Starka
Relationships of circulating pregnanolone isomers and their polar conjugates to the status of sex, menstrual cycle, and pregnancy
J. Endocrinol., October 1, 2007; 195(1): 67 - 78.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
J. M. Wang, P. B. Johnston, B. G. Ball, and R. D. Brinton
The Neurosteroid Allopregnanolone Promotes Proliferation of Rodent and Human Neural Progenitor Cells and Regulates Cell-Cycle Gene and Protein Expression
J. Neurosci., May 11, 2005; 25(19): 4706 - 4718.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
A. Parizek, M. Hill, R. Kancheva, H. Havlikova, L. Kancheva, J. Cindr, A. Paskova, V. Pouzar, I. Cerny, P. Drbohlav, et al.
Neuroactive Pregnanolone Isomers during Pregnancy
J. Clin. Endocrinol. Metab., January 1, 2005; 90(1): 395 - 403.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
F. M. Reis, D. D'Antona, and F. Petraglia
Predictive Value of Hormone Measurements in Maternal and Fetal Complications of Pregnancy
Endocr. Rev., April 1, 2002; 23(2): 230 - 257.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
M. V. St-Pierre, B. Hagenbuch, B. Ugele, P. J. Meier, and T. Stallmach
Characterization of an Organic Anion-Transporting Polypeptide (OATP-B) in Human Placenta
J. Clin. Endocrinol. Metab., April 1, 2002; 87(4): 1856 - 1863.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
J. D. Laiprasert, R. L. Hamlin, and C. M. Heesch
Afferent baroreceptor discharge in pregnant rats
Am J Physiol Heart Circ Physiol, December 1, 2001; 281(6): H2456 - H2462.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
B. E. P. Murphy
Allopregnanolone Assays
J. Clin. Endocrinol. Metab., March 1, 2001; 86(3): 1425 - 1425.
[Full Text]


Home page
J. Clin. Endocrinol. Metab.Home page
F. Petraglia
Author's Response: Allopregnanolone Assays
J. Clin. Endocrinol. Metab., March 1, 2001; 86(3): 1425a - 1425.
[Full Text]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Luisi, S.
Right arrow Articles by Genazzani, A. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Luisi, S.
Right arrow Articles by Genazzani, A. R.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals